Does microfracture repair actually hold up over time?

For patients who have been told microfracture is an option, the most pressing question is rarely anatomical — it is whether the repair will last. The honest answer, drawn from direct arthroscopic inspection, is that for a meaningful proportion of patients it does not.

A second-look arthroscopy study performed at a mean of 3.6 years after microfracture found that 36% of treated lesions remained incompletely healed, with inferior ICRS repair-tissue grades correlating directly with worse functional scores. The average MOCART score across the cohort was 67.8 — a figure that reflects partially filled defects and tissue that has not achieved the structural character of native cartilage. This is not a statistical outlier from a single centre; multiple papers published between 2024 and 2026 now describe a consistent pattern of 'midterm clinical deterioration', and one experimental study notes that microfracture 'often fails within 5 years' due to fibrocartilage insufficiency and accompanying subchondral bone damage.

The 2–3 year window when symptoms tend to return is not bad luck. It reflects a structural process that begins on the day of surgery and has been characterised in detail — and that characterisation is the starting point for understanding why alternative approaches are designed differently. The sections below explain the mechanism and set out what ChondroFiller injection offers as a contrast in both biological rationale and delivery.

Why the repair tissue microfracture produces is structurally inadequate

The sequence that determines repair quality is set in motion the moment the surgeon drills or picks through the subchondral bone plate. Perforating that plate releases bone marrow into the cartilage defect, and with it mesenchymal stem cells (MSCs) capable — in principle — of differentiating into cartilage-forming chondrocytes. The problem is not the cells themselves. It is the environment they arrive in.

The blood clot that fills the perforations lacks the biochemical signals required to guide MSCs toward hyaline chondrogenesis. Think of it as providing cells with the wrong raw materials and no instruction manual: without the cues that specifically direct Type II collagen synthesis, MSCs take the path of least resistance and default to producing fibrocartilage — a tissue dominated by Type I collagen rather than the Type II collagen that gives native articular cartilage its structural character.

This distinction matters beyond semantics. Fibrocartilage is not simply weaker cartilage; it is a structurally different tissue. Where hyaline cartilage is arranged in an organised, zonal architecture rich in proteoglycans — which retain water and distribute compressive load — fibrocartilage is isotropic and proteoglycan-poor. Under the cyclical compressive and shear forces of walking, stair-climbing, or sport, it stiffens, micro-cracks, and breaks down progressively rather than rebounding elastically.

Repeated micro-trauma to the deficient repair tissue does not stay confined to the surface. Over time, it propagates into the underlying subchondral bone plate, causing structural changes that narrow the options available for any subsequent cartilage restoration procedure — a compounding problem that surgeons and patients may only encounter years later.

What the mid-term evidence actually shows

Against that biological backdrop, the long-term evidence from augmented scaffold techniques sets a durability benchmark that standard microfracture cannot match. A mean 14-year follow-up of HA-BMAC one-step cartilage repair — where a hyaluronic acid matrix was combined with bone marrow aspirate concentrate — recorded a KOOS Pain score of 92, KOOS Sports Activity of 85, and KOOS Quality of Life of 88, with only 3 treatment failures in 26 patients. Those figures represent sustained functional preservation across a timeframe during which standard microfracture repairs characteristically deteriorate.

The orthopaedic field has responded to microfracture's limitations with so-called MFplus strategies — augmenting the standard technique with HA-based matrices, PRP, or BMAC to improve the biological environment at the repair site. A 92-patient RCT comparing a biphasic minced cartilage implant against microfracture illustrates both the promise and the current evidence gap: at 12 months, arthroscopic assessment showed more fully regenerated cartilage in the augmented group, yet IKDC functional scores were statistically comparable between groups. Whether improved tissue quality at one year translates into a divergent long-term trajectory remains to be answered — most current trials have not reached a follow-up point at which any difference would be expected to emerge.

No single large RCT has followed standard microfracture to 10 or more years with rigorous structural endpoints, so the picture is assembled from convergent data rather than one definitive source. What those sources consistently point toward is that the repair tissue itself is the rate-limiting variable. If fibrocartilage is the inevitable product of marrow stimulation without adequate biological direction, the natural question becomes whether a different mechanism — one that provides chemotactic signals from the outset — can produce a structurally different outcome.

How ChondroFiller injection works differently

ChondroFiller injection takes an entirely different starting point. Rather than perforating bone to release marrow, the treatment places an acellular Type I collagen hydrogel directly into the cartilage defect through an ultrasound-guided outpatient injection. Once positioned under image guidance, the gel sets in situ, forming a structural scaffold within the lesion — no operating theatre, no bone perforation, no requirement for an arthroscopic dry field.

The biological mechanism is matrix-induced chondrogenesis. The scaffold creates a chemotactic environment that draws the patient's own progenitor cells into the defect — a recruitment-led process rather than a release-led one. There is no surgically induced clot whose volume or biology determines whether useful cells arrive in adequate numbers. The approach is additive and non-ablative: existing cartilage tissue and the subchondral bone plate are left intact rather than debrided or perforated as a precondition for treatment.

Mechanistic confirmation of this cell-recruitment activity comes from ex vivo osteochondral explant data, which recorded a 2.4-fold increase in DNA content at day 14 in the ChondroFiller group compared with untreated defects. This is evidence that the scaffold actively draws cells in — not evidence of cartilage regrowth, which is a downstream biological process requiring sustained differentiation signals over a longer timeframe and is the subject of ongoing clinical investigation.

In practical terms, the contrast with microfracture is procedural as much as biological: where microfracture excavates and rebuilds from the subchondral bone upward, ChondroFiller injection works top-down — applying a protective, chemotactic matrix layer to what remains of the joint surface.

What the ChondroFiller outcome evidence shows — and where gaps remain

The clearest structural signal in the published literature comes from a prospective wrist study, where second-look arthroscopy showed significantly better cartilage quality in ChondroFiller-treated patients: median ICRS grade 1 versus grade 3 in controls (P=0.002), with Outerbridge scores following the same pattern. Functional data across joints — drawn from manufacturer-supported investigations — show IKDC scores improving by approximately 30 points from baseline, with MOCART scores in the range of 70–87. The reported complaint rate of approximately 0.06% is consistent with a well-tolerated outpatient injectable procedure.

Two evidence gaps deserve direct acknowledgement. First, no head-to-head RCT has compared ChondroFiller injection against microfracture at two or more years of follow-up. The available comparative context comes from studies of different designs, populations, and time horizons — not from a controlled comparison that would support a direct durability claim. Second, whether ChondroFiller produces hyaline-like repair tissue at the histological level rather than fibrocartilage has not been confirmed in peer-reviewed clinical series; the ex vivo cell-recruitment data speak to scaffold activity, not to the downstream phenotype of what regenerates.

What the current evidence does establish is the procedural distinction: no bone damage, no theatre requirement, and a safety profile consistent with other image-guided injectable treatments. The biological rationale is credible; the long-term durability data have not yet accumulated to the level available for established surgical alternatives.

Which patients are suitable — and what the next step looks like

Patient selection is the practical hinge on which all of this turns. Microfracture's declining use in contemporary cartilage practice reflects limitations now consistently documented in peer-reviewed literature — it is no longer the default first-line recommendation it once was, particularly where mid-term durability is the clinical priority.

ChondroFiller injection is suited to patients with focal defects graded ICRS 2–4 who are appropriate for an outpatient, non-surgical pathway; standard use covers lesions up to approximately 3 cm², with some applications extending to 6 cm². Larger defects, posttraumatic lesions, or cases where the subchondral bone is already compromised are more likely to require a surgical restoration discussion — MACI, ACI, or osteochondral allograft, depending on lesion characteristics and individual patient factors.

Alignment merits parallel consideration: mechanical load distribution shapes how any repair tissue performs over time, and where malalignment is present, osteotomy may need to be addressed alongside or before a cartilage intervention.

Determining which pathway fits requires a structured specialist assessment — imaging review, full lesion characterisation, and a shared decision about whether an injection-based or surgical route is most appropriate for the individual presentation. To arrange a cartilage assessment at the London Cartilage Clinic, visit londoncartilage.com.

1. [1] Arthroscopic Microfracture for Osteochondral Lesions of the Talus: Second-Look Arthroscopic and Magnetic Resonance Analysis. (2020). https://doi.org/10.2106/jbjs.19.00208 https://doi.org/10.2106/jbjs.19.00208
2. [2] The Effects of Irisin and Bevacizumab on Hyaline Cartilage Regeneration in Osteochondral Defects. (2025). https://doi.org/10.4055/cios24502 https://doi.org/10.4055/cios24502
3. [3] Injectable acellular matrix microgel assembly with stem cell recruitment and chondrogenic differentiation functions promotes microfracture-based articular cartilage regeneration. (2024). https://doi.org/10.1016/j.bioactmat.2024.10.013 https://doi.org/10.1016/j.bioactmat.2024.10.013
4. [4] Bionic ECM scaffolds for directional articular hyaline cartilage regeneration and long-term homeostasis maintenance. (2025). https://doi.org/10.1016/j.bioadv.2025.214292 https://doi.org/10.1016/j.bioadv.2025.214292
5. [5] One-Step Cartilage Repair of Full-Thickness Knee Chondral Lesions Using a Hyaluronic Acid–Based Scaffold Embedded With Bone Marrow Aspirate Concentrate: Long-term Outcomes After Mean Follow-up Duration of 14 Years. (2024). https://doi.org/10.1177/03635465241287524 https://doi.org/10.1177/03635465241287524
6. [6] Microfracture and Microfracture Plus of the Knee Joint. (2024). https://doi.org/10.1016/j.csm.2024.10.003 https://doi.org/10.1016/j.csm.2024.10.003
7. [7] Biphasic cartilage repair implant versus microfracture in the treatment of focal chondral and osteochondral lesions of the knee: a prospective, multi-center, randomized clinical trial. (2024). https://doi.org/10.1186/s10195-024-00802-1 https://doi.org/10.1186/s10195-024-00802-1
8. [8] Enhancing Cartilage Repair: Surgical Approaches, Orthobiologics, and the Promise of Exosomes. (2024). https://doi.org/10.3390/life14091149 https://doi.org/10.3390/life14091149
9. [9] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y